Co-Diagnostics 8-K: 2026 annual meeting adjourned without quorum; company to seek future special meeting
Co-Diagnostics, Inc. filed a Form 8-K on October 15, 2026 disclosing that its Annual Meeting of Stockholders, originally convened on September 3, 2026, failed to achieve a quorum on each of four attempts (September 3, September 24, September 30, and October 14, 2026) and was not further adjourned. No proposals were voted on at the Annual Meeting. The Company stated it currently intends to seek stockholder approval of the proposals that were to be considered at the Annual Meeting at a special meeting of stockhold...
Key takeaways
Annual meeting outcome: The 2026 Annual Meeting of Stockholders of Co-Diagnostics was unable to transact business after a quorum was not present or represented on October 14, 2026.
Multiple adjournments: The meeting was originally convened on September 3, 2026 and adjourned three times (September 24, September 30, and October 14, 2026) without achieving a quorum.
No further adjournment: The Company determined not to adjourn the October 14, 2026 reconvened meeting again.
Future special meeting planned: The Company currently intends to seek stockholder approval of the proposals at a special meeting of stockholders on a future date.
Pending disclosure: Date, time, location, and proxy materials for the special meeting were not disclosed in this 8-K and will be filed with the SEC and distributed to stockholders at a later date.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow CODX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.